Literature DB >> 32379575

Lipoprotein(a) Gets Worse.

Nathalie Pamir1, Sergio Fazio1.   

Abstract

Entities:  

Keywords:  Editorials; cardiovascular disease; lipoprotein (a); myocardial infarction; oxidized phospholipids; plasminogen

Mesh：

Substances：

Year:  2020        PMID： 32379575      PMCID： PMC7252907          DOI： 10.1161/CIRCRESAHA.120.316980

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  14 in total

1.  Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity.

Authors:  Hagai Tavori; Alexandra M Fenton; Deanna L Plubell; Sara Rosario; Elisabeth Yerkes; Rayna Gasik; Joshua Miles; Paige Bergstrom; Jessica Minnier; Sergio Fazio; Nathalie Pamir
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 2.  The PCSK9 revolution: Current status, controversies, and future directions.

Authors:  Bruce A Warden; Sergio Fazio; Michael D Shapiro
Journal:  Trends Cardiovasc Med       Date:  2019-05-21       Impact factor: 6.677

Review 3.  Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Nat Rev Cardiol       Date:  2019-05       Impact factor: 32.419

4.  Human plasma lipoprotein [a]. Structural properties.

Authors:  J W Gaubatz; C Heideman; A M Gotto; J D Morrisett; G H Dahlen
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

Review 5.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

6.  Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces.

Authors:  Mark A Hancock; Michael B Boffa; Santica M Marcovina; Michael E Nesheim; Marlys L Koschinsky
Journal:  J Biol Chem       Date:  2003-04-15       Impact factor: 5.157

7.  Plasminogen activator system in human coronary atherosclerosis.

Authors:  P N Raghunath; J E Tomaszewski; S T Brady; R J Caron; S S Okada; E S Barnathan
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-09       Impact factor: 8.311

8.  Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins.

Authors:  Anne von Zychlinski; Michael Williams; Sally McCormick; Torsten Kleffmann
Journal:  J Proteomics       Date:  2014-04-26       Impact factor: 4.044

9.  Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.

Authors:  Danish Saleheen; Philip C Haycock; Wei Zhao; Asif Rasheed; Adam Taleb; Atif Imran; Shahid Abbas; Faisal Majeed; Saba Akhtar; Nadeem Qamar; Khan Shah Zaman; Zia Yaqoob; Tahir Saghir; Syed Nadeem Hasan Rizvi; Anis Memon; Nadeem Hayyat Mallick; Mohammad Ishaq; Syed Zahed Rasheed; Fazal-Ur-Rehman Memon; Khalid Mahmood; Naveeduddin Ahmed; Philippe Frossard; Sotirios Tsimikas; Joseph L Witztum; Santica Marcovina; Manjinder Sandhu; Daniel J Rader; John Danesh
Journal:  Lancet Diabetes Endocrinol       Date:  2017-04-10       Impact factor: 32.069

10.  Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation.

Authors:  Johan G Schnitzler; Renate M Hoogeveen; Lubna Ali; Koen H M Prange; Farahnaz Waissi; Michel van Weeghel; Julian C Bachmann; Miranda Versloot; Matthew J Borrelli; Calvin Yeang; Dominique P V De Kleijn; Riekelt H Houtkooper; Marlys L Koschinsky; Menno P J de Winther; Albert K Groen; Joseph L Witztum; Sotirios Tsimikas; Erik S G Stroes; Jeffrey Kroon
Journal:  Circ Res       Date:  2020-03-12       Impact factor: 17.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.